Cargando…

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks

OBJECTIVES: Posthoc analysis of treatment satisfaction in patients switching to subcutaneous (SC) peginterferon beta-1a in the ALLOW study. PATIENTS AND METHODS: Patients with relapsing multiple sclerosis treated with intramuscular interferon (IFN) beta-1a or SC IFN beta-1a or beta-1b remained on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendin, Barry, Naismith, Robert T, Wray, Sibyl E, Huang, Deren, Dong, Qunming, Livingston, Terrie, Jones, Daniel L, Watson, Crystal, Jhaveri, Mehul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056153/ https://www.ncbi.nlm.nih.gov/pubmed/30050291 http://dx.doi.org/10.2147/PPA.S157317

Ejemplares similares

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
por: Naismith, Robert T, et al.
Publicado: (2019)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
por: Arnold, Douglas L., et al.
Publicado: (2018)

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study
por: Cohan, Stanley, et al.
Publicado: (2018)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
por: Menge, Til, et al.
Publicado: (2021)

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
por: Scott, Thomas F, et al.
Publicado: (2016)

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b
por: Weller, Ivonne, et al.
Publicado: (2015)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy
por: Zettl, Uwe Klaus, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach
por: White, Sarah, et al.
Publicado: (2021)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta
por: Zecca, Chiara, et al.
Publicado: (2014)

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
por: Taxonera, Carlos, et al.
Publicado: (2021)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
por: Newsome, Scott D., et al.
Publicado: (2018)

Multiple human beta interferon genes
Publicado: (1982)

Interferon-alpha-2a/peginterferon: Various toxicities: 6 case reports
Publicado: (2022)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Local Anesthesia in Every-Day Conservative Practice
por: Naismith, Alexander
Publicado: (1921)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Inhibition of suppressor T lymphocytes by murine interferon beta
Publicado: (1987)

Thrombotic microangiopathy associated with use of interferon-beta
por: Olea, Teresa, et al.
Publicado: (2012)

Interferon beta-1a–induced morphea
por: Bezalel, Spencer A., et al.
Publicado: (2014)

Interferon beta-1b for COVID-19
por: Shalhoub, Sarah
Publicado: (2020)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
por: Zhao, Yuan, et al.
Publicado: (2021)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Wittling, Megen C., et al.
Publicado: (2021)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta
Publicado: (1988)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
por: Sainz, Bruno, et al.
Publicado: (2005)

Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection
por: Schwerdtfeger, Mara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bebbiudv1ec8c0ftvnp1mi7hsn